Novo Nordisk and BioGeneriX acquire Neose's assets
This article was originally published in Scrip
Executive Summary
Neose Technologiesis to sell all its assets to its existing partners Novo NordiskandRatiopharm's subsidiary BioGeneriXfor a total of $43 million.